Cell Reports Medicine Impact Factor

The public current-release record shows a 2025 JIF of 14.0, up from 10.6 for

metric year 2024. That is a 3.4-point change between the two JCR releases now

available for this title. Cell Reports Medicine began publishing in 2020, so a

longer historical JIF series is not available from the records used here.

Do not infer a change in editorial selectivity, acceptance chance, or paper

quality from this two-point series. JIF is a journal-level citation metric, and

the publisher's scope remains the more useful input for deciding whether a

manuscript belongs in this venue.

The near-identical titles create a practical search and citation error. *Cell

Reports Medicine* is a premium open-access Cell Press journal for translational

and clinical biomedical research. Cell Reports is a separate life-sciences

journal with its own audience, scope, and metric record.

This distinction matters more than a family-name comparison. A manuscript with

strong mechanistic biology but no direct human-health relevance may fit a

different Cell Press title even when the citation metric looks attractive.

The JIF reports the average citation performance of recent articles in the

journal. A five-year JIF of 13.0 provides a longer citation window, while the

JCI of 2.33 is a field-normalized citation indicator. These values are useful

for describing the journal's citation position, but they do not measure whether

your study has the translational story the editors and readers expect.

The publisher describes the journal as serving research that informs and

influences human health and medicine. That means a target-journal decision

should start with the clinical or translational consequence of the work, then

use the metric as context. A high citation number does not turn a basic,

single-system result into a clinical or translational manuscript.

Taken together, the JIF is 14.0 and the 5-year JIF is

13.0. The CiteScore of 14.6, SJR of 4.028, and SNIP of 1.803 describe different

journal-level citation views. They do not show the strength of an individual

result, whether a cohort is adequate, or whether a proposed clinical implication

is supported.

In our analysis of the public journal record, we checked the 2026 JCR title record, the publisher's scope description, the

Scopus metric record, and the NLM title record before separating this owner

from Cell Reports. The publisher describes original research from human

biology, health, and disease through clinical work, and explicitly includes

translational studies, clinical trials, genomics, biomarker discovery, and

diagnostic or treatment-relevant technology. The useful decision is not whether

14.0 is "high" in the abstract. It is whether the manuscript's contribution

can be stated in that translational and clinical frame without overstating the

data.

We find that the high-impression query needs an exact-title answer before any

metric interpretation: the existing Cell Reports owner cannot supply this

journal's JIF without creating a title-level attribution error.

Three metric-reading errors are especially avoidable:

• Title-family substitution. A citation, CV line, or journal comparison

uses Cell Reports data for Cell Reports Medicine. Confirm the full title

and eISSN before using any number.

• Citation-first targeting. The abstract leads with a molecular finding,

but does not establish what changes for human health, disease, diagnosis, or

treatment. The scope is a fit test, not a decoration for the cover letter.

• Metric-only comparison. A manuscript is compared only on JIF with a

basic-biology title. Compare the reader, evidence package, clinical context,

and translational claim before comparing citation indicators.

• Process substitution. A current publisher page reports aggregate timing

information, but that is not a guarantee that a particular paper will be

reviewed, accepted, or published on that schedule. Check the live

submission portal and

author instructions before acting on a date-sensitive requirement.

We did not infer an acceptance rate, decision time, APC, or editorial threshold

from the JIF. Those are separate, changeable facts and should be checked on the

current publisher page before a submission decision. This review is limited to

the public title, metric, and scope records cited below; it is not a benchmark

of manuscript outcomes or a claim about editorial decision-making.

For a reader using the page as a lookup, that boundary is intentional: the

exact title and current JCR record can be checked, while manuscript suitability

requires an inspection of the abstract, methods, figures, and evidence claim.

For a manuscript that is close to submission, a [Cell Reports Medicine

readiness check](/ai-review?target_journal=Cell%20Reports%20Medicine&primary_concern=journal_fit)

can help test whether the abstract, claims, figures, and evidence package make

the translational relevance clear enough for the intended audience.

The metric cannot tell you whether a study has the clinical relevance the scope

requires, whether a human cohort or disease model is sufficient for the claim,

or whether a different audience would make the paper easier to evaluate. It

also does not replace the current author instructions, publication agreement,

or journal-specific policy check.

Use the current publisher instructions to check the article type, submission

route, author list, data and ethics documentation, and any applicable funding

or open-access requirements. The publisher currently lists original research,

reports, tools, datasets, and reviews among the formats it considers, but the

appropriate format depends on the contribution. A six-day first-decision

figure is a reported journal aggregate, not a promise for a specific manuscript.

For fit, keep the abstract and key figures aligned: state the human-health or

clinical consequence, identify the evidence that supports it, and make any

model-system limitation visible. A study that uses a vertebrate model should

be able to explain its direct relevance to human health and disease, consistent

with the published scope. A [translational manuscript readiness

check](/ai-review?target_journal=Cell%20Reports%20Medicine&primary_concern=claim_evidence_alignment)

can help compare the claim language with the evidence package before submission.

record for Cell Reports Medicine, eISSN 2666-3791.

• Cell Reports Medicine journal profile

for publisher, scope, and journal identity.

• Cell Reports Medicine presubmission inquiry

for the journal's translational and clinical positioning.

• NLM Catalog record

for the exact title and eISSN.

• University of Twente journal browser

for the 2024 Scopus CiteScore, SJR, and SNIP values.

*Last reviewed July 14, 2026. Journal metrics and publisher policies can

change; verify the current JCR and journal record before formal use.*